APA (7th ed.) Citation

JF, C., C, M., PB, L., SS, P., BT, C., N, J., . . . GE, L. (2023). Therapeutic targeting of immunometabolism in Alzheimer's disease reveals a critical reliance on Hexokinase 2 dosage on microglial activation and disease progression. BioRxiv : the preprint server for biology. https://doi.org/10.1101/2023.11.11.566270

Chicago Style (17th ed.) Citation

JF, Codocedo, Mera-Reina C, Lin PB, Puntambekar SS, Casali BT, Jury N, Martinez P, Lasagna-Reeves CA, and Landreth GE. "Therapeutic Targeting of Immunometabolism in Alzheimer's Disease Reveals a Critical Reliance on Hexokinase 2 Dosage on Microglial Activation and Disease Progression." BioRxiv : The Preprint Server for Biology 2023. https://doi.org/10.1101/2023.11.11.566270.

MLA (9th ed.) Citation

JF, Codocedo, et al. "Therapeutic Targeting of Immunometabolism in Alzheimer's Disease Reveals a Critical Reliance on Hexokinase 2 Dosage on Microglial Activation and Disease Progression." BioRxiv : The Preprint Server for Biology, 2023, https://doi.org/10.1101/2023.11.11.566270.